| MEDTRONIC-AGREEMENT-ORCHESTRA-BIOMED-INC |
MEDTRONIC-AGREEMENT-ORCHESTRA-BIOMED-INC |
85%
|
ercialization following receipt of regulatory approvals, including manufacturing, sales, marketing and distribution costs. The Company is expected to receive between $ 500 and $ 1,600 per AVIM-enable… |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from ABT graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from ABT grap… |
| ABT |
Abbott Laboratories |
72%
|
ve interventional cardiology field include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, Abbott Laboratories, Cordis, BIOTRONIK, Inc., Concept Medical, Inc.,… |
| BSX |
Boston Scientific Corporation |
72%
|
ve interventional cardiology field include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, Abbott Laboratories, Cordis, BIOTRONIK, Inc., Concept Medical, Inc.,… |
| BSX |
Boston Scientific Corporation |
72%
|
Reciprocal relationship from BSX graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from BSX graph: Reciprocal relationship from OBIO graph: ve interventional cardiology field in… |
| HTGC |
Hercules Capital, Inc. |
72%
|
Reciprocal relationship from HTGC graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from HTGC g… |
| HTGC |
Hercules Capital, Inc. |
72%
|
ares”), at an exercise price equal to $ 3.67 per share. The exercise price of the Ligand Warrants and the number of Ligand Warrant Shares issuable upon exercise of the Ligand Warrants are subject to … |
| LGND |
Ligand Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from LGND graph: Reciprocal relationship from OBIO graph: e determined that the arrangement set forth in the Medtronic Agreement as amended by the Medtronic Agreement Amendmen… |
| LGND |
Ligand Pharmaceuticals Incorporated |
72%
|
e determined that the arrangement set forth in the Medtronic Agreement as amended by the Medtronic Agreement Amendment (the “Amended Medtronic Agreement”) is a collaboration within the scope of ASC 8… |
| MDT |
Medtronic plc |
72%
|
Reciprocal relationship from MDT graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from MDT graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from MDT grap… |
| MDT |
Medtronic plc |
72%
|
eceipt of the shipping invoices. Upfront payments are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded a… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from OBIO graph: functional, the corresponding provisions of the EU Medical Devices Directives continue to apply. A serious incident … |
| ORANY |
ORANY |
72%
|
functional, the corresponding provisions of the EU Medical Devices Directives continue to apply. A serious incident is defined as any malfunction or deterioration in the characteristics or performanc… |
| ABBOTT-LABORATORIES-BOSTON-SCIENTIFIC-CORPORATIO |
ABBOTT-LABORATORIES-BOSTON-SCIENTIFIC-CORPORATIO |
62%
|
ng Virtue SAB, our most notable competitors in the highly competitive interventional cardiology field include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, A… |
| BACKBEAT-MEDICAL-LLC |
BACKBEAT-MEDICAL-LLC |
62%
|
had $71.8 million of short-term marketable securities at December 31, 2025, which consisted primarily of our investments in corporate debt securities. 78 Table of Contents We currently have a lim… |
| CALIBER-THERAPEUTICS-INC |
CALIBER-THERAPEUTICS-INC |
62%
|
DE”) pivotal study randomizing Virtue SAB vs. Boston Scientific Corporation’s AGENT™ drug-coated balloon. Designed to support regulatory approval of Virtue SAB, the Virtue Trial is expected to enroll… |
| CALIBER-THERAPEUTICS-LLC |
CALIBER-THERAPEUTICS-LLC |
62%
|
had $71.8 million of short-term marketable securities at December 31, 2025, which consisted primarily of our investments in corporate debt securities. 78 Table of Contents We currently have a lim… |
| CONCEPT-MEDICAL-INC-MICROPORT-EUROCOR-TECH-GMBH |
CONCEPT-MEDICAL-INC-MICROPORT-EUROCOR-TECH-GMBH |
62%
|
ng Virtue SAB, our most notable competitors in the highly competitive interventional cardiology field include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, A… |
| COVIDIEN-GROUP |
COVIDIEN-GROUP |
62%
|
ercialization following receipt of regulatory approvals, including manufacturing, sales, marketing and distribution costs. The Company is expected to receive between $ 500 and $ 1,600 per AVIM-enable… |
| FREEHOLD-SURGICAL-LLC |
FREEHOLD-SURGICAL-LLC |
62%
|
had $71.8 million of short-term marketable securities at December 31, 2025, which consisted primarily of our investments in corporate debt securities. 78 Table of Contents We currently have a lim… |
| ORCHESTRA-BIOMED-INC |
ORCHESTRA-BIOMED-INC |
62%
|
controlled HTN despite the use of anti-hypertensive medications (the “Medtronic Agreement”). On July 31, 2025, our wholly owned subsidiaries, Orchestra BioMed, Inc. and BackBeat, and Medtronic entere… |
| PHILIPS-N-V-B-BRAUN-ABBOTT-LABORATORIES-CORDIS-T |
PHILIPS-N-V-B-BRAUN-ABBOTT-LABORATORIES-CORDIS-T |
62%
|
ng Virtue SAB, our most notable competitors in the highly competitive interventional cardiology field include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, A… |
| S-L-U-BIOSENSORS-INTERNATIONAL-GROUP-LTD-BALTON- |
S-L-U-BIOSENSORS-INTERNATIONAL-GROUP-LTD-BALTON- |
62%
|
ng Virtue SAB, our most notable competitors in the highly competitive interventional cardiology field include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, A… |
| TERUMO-MEDICAL-CORPORATION |
TERUMO-MEDICAL-CORPORATION |
62%
|
thorized to issue up to 340,000,000 shares of Common Stock. Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $ 0.0001 per share. The board o… |
| USA-LLC |
USA-LLC |
62%
|
ion, we can receive up to approximately $10.7 million of proceeds in 2026 associated with the transaction. In January, we received the initial upfront payment of $4.7 million and the remainder may be… |
| VIVASURE-MEDICAL-LIMITED |
VIVASURE-MEDICAL-LIMITED |
62%
|
ve months following the LSA Closing Date, (b) 2.0% of the Term Loans being prepaid if the prepayment occurs after 12 months following the LSA Closing Date but on or prior to 24 months following the L… |
